Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319495 | 0.82 | MDM2 (0.54) | MDM2TP53KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1319361 | 0.81 | MDM2 (0.52) | MDM2TP53KMT2AADAMTS5 | |
| SCHEMBL1320116 | 0.80 | MDM2 (0.47) | MDM2TP53LMNAMAPK1ALDH1A1 | |
| SCHEMBL8196615 | 0.80 | MDM2 (0.47) | MDM2TP53LMNAMAPK1ALDH1A1 | |
| SCHEMBL1321543 | 0.80 | MDM2 (0.48) | MDM2TP53KMT2AEPHX2 | |
| SCHEMBL1323284 | 0.80 | TDP1 (0.45) | MDM2TP53KMT2AL3MBTL1LMNA | |
| SCHEMBL1320737 | 0.79 | MDM2 (0.49) | MDM2TP53ADAMTS5OPRK1 | |
| SCHEMBL1321163 | 0.79 | MDM2 (0.54) | MDM2TP53KMT2ALMNAALDH1A1 | |
| SCHEMBL1319453 | 0.79 | MDM2 (0.53) | MDM2TP53KMT2ALMNAALDH1A1 | |
| SCHEMBL1319899 | 0.79 | MDM2 (0.53) | MDM2TP53LMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058269-B2 | rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins | HOFFMAN-LA ROCHE INC. (US) | 2011-11-15 | — | — | US | claimed |
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | claimed |
| EP-2066318-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | claimed |
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CHEN LI | 2008-04-03 | — | — | US | claimed |
| WO-2008034736-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | claimed |
| US-8058269-B2 | rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins | HOFFMAN-LA ROCHE INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| EP-2066318-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CHEN LI | 2008-04-03 | — | — | US | disclosed |
| WO-2008034736-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CCNY, CCNI, RPS4Y1 | MDM2 441/4885TP53 219/4885KMT2A 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.